文献速递眼底病与葡萄膜炎

已获批的基于人工智能的流体监测用于识别新生血管性年龄相关性黄斑变性在真实世界常规诊疗中的形态学和功能学治疗结局

Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine.
PubMed 文献 · Br J Ophthalmol · 2024-06-20

该研究在苏黎世Fight Retinal Blindness!注册登记的真实世界队列中,对158例未接受过治疗的新生血管性年龄相关性黄斑变性(nAMD)患者的202只眼,利用深度学习算法(Vienna Fluid Monitor)分割视网膜内液、视网膜下液和色素上皮脱离体积,并构建机器学习模型预测抗VEGF治疗需求及形态学结局。结果显示,预测第一年注射次数中位分组的平均AUC为0.77(95%CI 0.71至0.83),预测4年黄斑萎缩的平均AUC为0.70(95%CI 0.61至0.79),预测视网膜下纤维化的AUC为0.74(95%CI 0.63至0.81)。结论认为,监管批准的AI流体监测可让临床医生使用自动化算法前瞻性指导AMD患者治疗,且视网膜流体定位和量化可预测长期形态学结局。

要点

  • AI流体监测预测第一年注射次数中位分组的平均AUC为0.77(95%CI 0.71至0.83)。
  • 基线最佳矫正视力是决定1年后最终视力结局的最相关预测因素。
  • 模型区分4年黄斑萎缩的平均AUC为0.70(95%CI 0.61至0.79),预测视网膜下纤维化的AUC为0.74(95%CI 0.63至0.81)。

核心结论

  • 监管批准的AI流体监测允许临床医生在AMD治疗中使用自动化算法前瞻性指导患者治疗。
  • 视网膜流体定位和量化可预测长期形态学结局。

研究设计与样本

  • 研究为真实世界队列,数据来自苏黎世Fight Retinal Blindness!注册登记。
  • 纳入158例未接受过治疗的nAMD患者,共评估202只眼。
  • 对基线和初始玻璃体内抗VEGF治疗后的谱域光学相干断层扫描数据进行分析,以预测后续1年和4年结局。
  • 使用深度学习算法(Vienna Fluid Monitor,RetInSight,奥地利维也纳)分割视网膜内液、视网膜下液和色素上皮脱离体积。
  • 利用计算的定量特征集构建预测未来治疗需求和形态学结局的机器学习模型。

主要发现

  • 第一年注射次数中位较低组(≤7次)为107只眼,中位较高组(≥8次)为95只眼,预测平均AUC为0.77(95%CI 0.71至0.83)。
  • 基线最佳矫正视力是决定1年后最终视力结局的最相关预测因素。
  • 4年内半数眼进展为黄斑萎缩,模型区分黄斑萎缩与非黄斑萎缩眼的平均AUC为0.70(95%CI 0.61至0.79)。
  • 预测视网膜下纤维化的AUC为0.74(95%CI 0.63至0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To predict antivascular endothelial growth factor (VEGF) treatment requirements, visual acuity and morphological outcomes in neovascular age-related macular degeneration (nAMD) using fluid quantification by artificial intelligence (AI) in a real-world cohort. METHODS: Spectral-domain optical coherence tomography data of 158 treatment-naïve patients with nAMD from the Fight Retinal Blindness! registry in Zurich were processed at baseline, and after initial treatment using intravitreal anti-VEGF to predict subsequent 1-year and 4-year outcomes. Intraretinal and subretinal fluid and pigment epithelial detachment volumes were segmented using a deep learning algorithm (Vienna Fluid Monitor, RetInSight, Vienna, Austria). A predictive machine learning model for future treatment requirements and morphological outcomes was built using the computed set of quantitative features. RESULTS: Two hundred and two eyes from 158 patients were evaluated. 107 eyes had a lower median (≤7) and 95 eyes had an upper median (≥8) number of injections in the first year, with a mean accuracy of prediction of 0.77 (95% CI 0.71 to 0.83) area under the curve (AUC). Best-corrected visual acuity at baseline was the most relevant predictive factor determining final visual outcomes after 1 year. Over 4 years, half of the eyes had progressed to macular atrophy (MA) with the model being able to distinguish MA from non-MA eyes with a mean AUC of 0.70 (95% CI 0.61 to 0.79). Prediction for subretinal fibrosis reached an AUC of 0.74 (95% CI 0.63 to 0.81). CONCLUSIONS: The regulatory approved AI-based fluid monitoring allows clinicians to use automated algorithms in prospectively guided patient treatment in AMD. Furthermore, retinal fluid localisation and quantification can predict long-term morphological outcomes.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mares V, Schmidt-Erfurth UM, Leingang O, et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br J Ophthalmol. 2024. PMID: 37775259. doi:10.1136/bjo-2022-323014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。